These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Conflicting roles of 20-HETE in hypertension and renal end organ damage. Zhang C; Booz GW; Yu Q; He X; Wang S; Fan F Eur J Pharmacol; 2018 Aug; 833():190-200. PubMed ID: 29886242 [TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Jessup JA; Gallagher PE; Averill DB; Brosnihan KB; Tallant EA; Chappell MC; Ferrario CM Am J Physiol Heart Circ Physiol; 2006 Nov; 291(5):H2166-72. PubMed ID: 16766648 [TBL] [Abstract][Full Text] [Related]
10. 20-Hydroxyeicosatetraenoic Acid (HETE)-dependent Hypertension in Human Cytochrome P450 (CYP) 4A11 Transgenic Mice: NORMALIZATION OF BLOOD PRESSURE BY SODIUM RESTRICTION, HYDROCHLOROTHIAZIDE, OR BLOCKADE OF THE TYPE 1 ANGIOTENSIN II RECEPTOR. Savas Ü; Wei S; Hsu MH; Falck JR; Guengerich FP; Capdevila JH; Johnson EF J Biol Chem; 2016 Aug; 291(32):16904-19. PubMed ID: 27298316 [TBL] [Abstract][Full Text] [Related]
11. 20-HETE Activates the Transcription of Angiotensin-Converting Enzyme via Nuclear Factor-κB Translocation and Promoter Binding. Garcia V; Shkolnik B; Milhau L; Falck JR; Schwartzman ML J Pharmacol Exp Ther; 2016 Mar; 356(3):525-33. PubMed ID: 26699146 [TBL] [Abstract][Full Text] [Related]
12. NRF2 prevents hypertension, increased ADMA, microvascular oxidative stress, and dysfunction in mice with two weeks of ANG II infusion. Wang C; Luo Z; Carter G; Wellstein A; Jose PA; Tomlinson J; Leiper J; Welch WJ; Wilcox CS; Wang D Am J Physiol Regul Integr Comp Physiol; 2018 Mar; 314(3):R399-R406. PubMed ID: 29167164 [TBL] [Abstract][Full Text] [Related]
13. Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension. Xia H; Sriramula S; Chhabra KH; Lazartigues E Circ Res; 2013 Oct; 113(9):1087-1096. PubMed ID: 24014829 [TBL] [Abstract][Full Text] [Related]
15. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Ferrario CM; Jessup J; Gallagher PE; Averill DB; Brosnihan KB; Ann Tallant E; Smith RD; Chappell MC Kidney Int; 2005 Nov; 68(5):2189-96. PubMed ID: 16221218 [TBL] [Abstract][Full Text] [Related]
16. Antihypertensive activity of Salvia elegans Vahl. (Lamiaceae): ACE inhibition and angiotensin II antagonism. Jiménez-Ferrer E; Badillo FH; González-Cortazar M; Tortoriello J; Herrera-Ruiz M J Ethnopharmacol; 2010 Jul; 130(2):340-6. PubMed ID: 20488233 [TBL] [Abstract][Full Text] [Related]
17. Hypertension: renin-angiotensin-aldosterone system alterations. Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283 [TBL] [Abstract][Full Text] [Related]
18. Local renin-angiotensin system mediates endothelial dilator dysfunction in aging arteries. Flavahan S; Chang F; Flavahan NA Am J Physiol Heart Circ Physiol; 2016 Sep; 311(3):H849-54. PubMed ID: 27422988 [TBL] [Abstract][Full Text] [Related]
19. The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease. Goto M; Hoxha N; Osman R; Dell KM Pediatr Nephrol; 2010 Dec; 25(12):2449-57. PubMed ID: 20798958 [TBL] [Abstract][Full Text] [Related]
20. 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Sedláková L; Kikerlová S; Husková Z; Červenková L; Chábová VČ; Zicha J; Falck JR; Imig JD; Kompanowska-Jezierska E; Sadowski J; Krátký V; Červenka L; Kopkan L Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30054426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]